With the EU Regulation 2025/1466 Key requirements for the Pharmacovigilance (PV) Noticeably, the focus is shifting away from pure formalism towards Traceability, process quality and transparent documentation. For pharmaceutical companies, this means specifically: PV processes must not only function, but proven, versioned and auditable be, and that is along the entire process chain from detection to action. 

This increases expectations for the organization, IT systems, and governance alike. In particular, the following are required: 

• Complete documentation of PV-relevant content and decisions 

• Risk-based assessment of deviations and process risks 

• Rapid response to potentially critical messages 

• international data standards and consistent chains of evidence 

• Audit and inspection capability for internal and regulatory audits 

evalii® It provides the technological and procedural foundation for this. The platform supports companies not only in meeting regulatory requirements, but also in... to actively control. 

 evalii® is a structured system for monitoring, evaluation and Documentation of potentially pharmacovigilance-relevant content, especially from digital channels. This is precisely where a practical problem often lies: While companies can often monitor social media, contact forms, or platform comments, the regulatory-required documentation is often manual, fragmented, and not consistently audit-proof. 

evalii® provides a solution here by handling all process steps standardized and understandable be depicted. 

The platform helps answer key audit questions such as: 

• Which message was detected and when? 

• How was it evaluated, classified, and prioritized? 

• To whom was it forwarded and when? 

• Who was involved and what measures were taken? 

This creates a transparent, audit-proof workflow, which can be adapted to existing role models and SOPs. 

 The new EU regulation reinforces the requirement that PV processes not only be "lived" but also formally verifiable must be. In practice, this means that companies need documented proof that..., 

• that PV-relevant content identified become, 

• like her rated become, 

• how decisions are made, 

• and which Measures were hit. 

With evalii®, this documentation no longer becomes a manual effort.  

This particularly supports: 

Compliance with new PSMF (Pharmacovigilance System Master File) requirements 

The demands placed on the PV system and its documentation are increasing. evalii® enables the consistent mapping of process logic, responsibilities, and decision-making paths – an essential foundation for auditable PV documentation. 

Risk-based assessment of process deviations 

Instead of blanket formalism, risk-based analysis takes center stage: Which deviations are critical? Which are tolerable? What measures are required? evalii® provides structured data foundations for this. 

Audits require a complete and transparent justification of decisions and responsibilities. evalii® provides a comprehensive history for this purpose: Who assessed what, when, and why? This reduces audit effort and provides security when dealing with regulatory inquiries. 

Digital channels are now a key risk factor and, at the same time, a crucial information space. Continuous monitoring is therefore not only an organizational obligation but increasingly a governance requirement: companies must ensure that relevant content is identified and assessed before it gives rise to regulatory or liability risks. 

evalii® offers not only safety, but a genuine Early warning function: 

• Potentially critical content is identified. 

• prioritized and classified 

• assigned to the relevant authorities 

• and documented along the process chain 

This creates responsiveness – and at the same time the required verifiability. 

 Conclusion:  

The new EU regulation requires transparency, reaction speed and documented quality. Companies are therefore faced with the task of not only making PV processes more efficient, but above all Auditable and revision-proof to build. 

evalii® offers a solution that meets regulatory requirements structured representation, Effort reduced and supports companies in implementing modern PV standards. 

With evalii®, the switch to... modern pharmacovigilance. 

Der Beitrag Regulatorische Anforderungen mit evalii® umsetzen: EU-Verordnung 2025/1466, Pharmakovigilanz und auditfähige Prozesse erschien zuerst auf evalii - pharmacovigilance monitoring service.

Pharmacovigilance legislation is continually being revised to respond to new scientific evidence and technological developments. This dynamism ensures that the legal provisions remain effective and continue to ensure patient protection. 

In the European Union, pharmacovigilance is strictly regulated in order to ensure a high level of protection for the health of citizens. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use sets out the legal basis for the authorisation, monitoring and pharmacovigilance of medicinal products in the EU. This is supplemented by Regulation (EC) No. 726/2004, which establishes a centralised procedure for the authorisation and monitoring of medicinal products. These directives oblige member states and pharmaceutical companies to implement strict pharmacovigilance practices. 

The importance of pharmacovigilance was particularly highlighted by the revision of this legislation in 2012, which strengthened the EU-wide system for monitoring drug safety and re-emphasized the specific responsibility for the safety of medicines. These changes, introduced by Directive 2010/84/EU and Regulation (EU) No 1235/2010, improved the transparency and public accessibility of information on the safety of medicines and strengthened the role of the European Medicines Agency (EMA) in pharmacovigilance. 

A crucial part of this framework are the Guidelines on Good Pharmacovigilance Practices (GVP), specifically Modules I and VI. These provide detailed instructions on how to carry out pharmacovigilance activities and are crucial for understanding how companies should fulfil their legal obligations. 

The GVP is critical to ensuring that pharmacovigilance practices are not only effective but also standardized, leading to improved drug safety and patient protection. By following these guidelines, companies ensure that they can proactively respond to potential risks and that they act in accordance with best practices and legal requirements. 

Compliance with GVP is required by law in the European Union. These guidelines are part of the regulatory framework set by the European Medicines Agency (EMA) to ensure that all pharmaceutical companies adhere to uniform standards in monitoring the safety of medicines. Failure to comply can result in legal sanctions. 

Furthermore, compliance with GVP is often a prerequisite for access to international markets. Regulatory authorities worldwide recognize European Union standards and expect similar practices from companies wishing to operate in their jurisdictions. 

In Germany, the Medicines Act (AMG) is the legal basis that regulates the safety of medicinal products, including pharmacovigilance requirements. The AMG implements EU directives into national law and ensures that medicinal products are monitored throughout their entire life cycle. The federal authorities, in particular the Federal Institute for Drugs and Medical Devices (BfArM) and the Paul Ehrlich Institute (PEI), are vested with extensive powers to monitor and enforce compliance with pharmacovigilance regulations. 

The legal framework also covers international cooperation between national authorities and the EMA. Coordination and information exchange are crucial for monitoring drug safety across borders. 

In a strictly regulated environment such as the pharmaceutical industry, understanding and implementing regulations and guidelines is not only a legal necessity, but also an essential part of corporate ethics and public trust. Pharmacovigilance is an indispensable part of the healthcare system in Germany and Europe. 

In conclusion, evalii® as a professional solution for pharmacovigilance monitoring not only meets a legal requirement, but also represents a strategic asset for pharmaceutical companies. Through automated, continuous monitoring and documentation of communication channels, evalii® makes an indispensable contribution to compliance with strict international pharmacovigilance regulations. The integration of state-of-the-art technologies not only guarantees compliance with current legislation, but also positions evalii® as a pioneer in efficient risk minimization and safety monitoring in the pharmaceutical sector. This makes evalii® the optimal choice for companies that value the highest standards in drug safety and the protection of public health. 

Der Beitrag Juristische Hintergründe – weshalb die PV in Deutschland und Europa so wichtig ist  erschien zuerst auf evalii - pharmacovigilance monitoring service.